Considering the P450 cytochrome system as determining combined effects of antidepressants and benzodiazepines on actual driving performance of depressed outpatients

International Clinical Psychopharmacology

Volumn 12, Issue 3, 1997, Pages 159-169

  Ramaekers, J G ^a   Ansseau, M ^b   Muntjewerff, N D ^a   Sweens, J P ^a   O'Hanlon, J F ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b CHU SART TILMAN   (Belgium)

Author keywords

Benzodiazepines; CYP2C19; CYP3A3 4; Depression; Driving; Drug interactions; Fluoxetine; Moclobemide

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BROMAZEPAM; CLORAZEPATE; CLOTIAZEPAM; CLOXAZOLAM; CYTOCHROME P450 ISOENZYME; DIAZEPAM; FLUOXETINE; LORAZEPAM; MOCLOBEMIDE; OXAZEPAM; PRAZEPAM;

ADULT; AGITATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRIVING ABILITY; FEMALE; HUMAN; MALE; MULTIPLE REGRESSION; NAUSEA; NERVOUSNESS; ORAL DRUG ADMINISTRATION; OUTPATIENT; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SLEEP DISORDER; VERTIGO; XEROSTOMIA;

EID: 0030738311     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-199705000-00007     Document Type: Article

References (27)

1. Andersson T, Miners JO, Veronese ME and Birkett DJ (1994) Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms. Journal of Clinical Psychopharmacology, 15, 131-137.
2. Ansseau M (1988) The pharmacological treatment of anxiety. Revue Médicale de Liège, 43, 80-91.
3. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Säwe J and Villén T (1989) Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not to debrisoquin, hydroxolation phenotype. Clinical Pharmacology and Therapeutics, 45, 348-355.
4. Brøsen K (1993) Isozyme specific drug oxidation: genetic polymorphism and drug-drug interactions. Nordic Journal of Psychiatry, 47(suppl), 21-26.
5. Caraco Y, Tateishi T and Wood AJJ (1995) Interethnic differences in omeprazole's inhibition of diazepam metabolism. Clinical Pharmacology and Therapeutics, 1, 62-72.
6. Goldstein JA, Faletto MB and Romkes-Sparks M (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry, 33, 1743-1752.
7. Gram LF, Guentert TW, Grange S, Vistisen K and Brøsen K (1995) Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6 and CYP 1A2: a panel study. Clinical Pharmacology and Therapeutics, 57, 670-677.
8. Guentert TW, Grange S, Bock J, Waldburger R and Birnboeck H (1995) Lack of an important influence of CYP2D6 oxidation status on the pharmacokinetics of moclobemide. Clinical Pharmacology and Therapeutics, 57, 151.
9. Ketter TA, Flockhart DA Post RM, Denicoff K, Pazzaglia PJ, Marangell LB, George MS and Callahan AM (1995) The emerging role of cytochrome P450 3A in psychopharmacology. Journal of Clinical Pharmacology, 15, 387-398.
10. Kroboth PD, Folan MM, Lusch RM, Chaikin PC, Shukla UA, Barbaiya R and Salazar DE (1995) Coadministration of nefazodone and benzodiazepines: I pharmacodynamic assessment. Journal of Clinical Pharmacology, 15, 306-319.
11. Lane R, Baldwin D and Preskorn S (1995) The SSRIs: advantages, disadvantages and differences. Journal of Psychopharmacology, 9 (suppl), 163-178.
12. Lasher TA, Fleishaker JC, Steenwyck RC and Antal EJ (1991) Pharmacokinetic, pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology, 104, 323-327.
13. Lemberger L, Rowe H, Bosomworth JC, Tenbarge JB and Bergstrom RF (1988) The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clinical Pharmacology and Therapeutics, 43, 412-419.
14. Leveille SG, Buchner DM, Koepsell TD, McClosky LW, Wolf ME and Wagner EH (1994) Psychoactive medications and injurious motor vehicle collisions involving older drivers. Epidemiology, 5, 591-598.
15. Louwerens JW, Gloerich ABM, de Vries G, Brookhuis KA and O'Hanlon JF (1987) The relationship between drivers' blood alcohol concentration (BAC) and actual driving performance during high speed travel. In: Alcohol, Drugs and Traffic Safely - T86 (Eds PC Noordzij and R Roszbach) pp. 183-186. Excerpta Medica, Amsterdam.
16. Nelson RC (1986) Psychotherapeutic drugs, mental disorders and automobile crashes: a case-control study of 1308 females [Dissertation]. Minneapolis, Minnesota: University of Minnesota.
17. Neutel CI (1995) Risk of traffic accident injury after a prescription for a benzodiazepine. Pharmacoepidemiology, 5, 239-244.
18. Ochs HR, Greenblatt DJ, Verbyrg-Ochs B, Harmatz JS and Grehl H (1984) Disposition of clotiazepam: influence of age, sex, oral contraceptives, cimetidine, isoniazid and ethanol. European Journal of Clinical Pharmacology, 26, 55-59.
19. O'Hanlon JF, Vermeeren A, Uiterwijk MMC, Veggel van LMA and Swijgman HF (1995) Anxiolytics' effects on the actual driving performance of patients and healthy volunteers in a standardized test. Neuropsychobiology, 31, 81-88.
20. Petit N, Delporte JP, Ansseau M, Albert A and Jeusette F (1994) Drug utilization review of oral forms of benzodiazepines in a Belgian 635-bed teaching hospital. Pharmacy World and Science, 16, 181-186.
21. Ray WA, Fought RL and Decker MD (1992) Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly. American Journal of Epidemiology, 136, 873-883.
22. Ramaekers JG, Swijgman HF and O'Hanlon JF (1992) Effects of moclobemide and mianserin on highway driving, psychometric performance and subjective parameters, relative to placebo. Psychopharmacology, 106(suppl), 62-67.
23. Ramaekers JG, Muntjewerff ND and O'Hanlon JF (1995) A comparative study of the acute and subchronic effects of dothiepin, fluoxetine and placebo on psychomotor and actual driving performance. British Journal of Clinical Pharmacology, 39, 397-404.
24. Van Harten J, Holland RL and Wesnes K (1992) Influence of multiple dose administration of fluvoxamine on the pharmacokinetics of the benzodiazepines bromazepam and lorazepam: a randomized, cross-over study. European Neuropharmacology, 2, 281.
25. Van Laar M, Volkerts ER and Willigenburg van APP (1992) Therapeutic effects and effects on actual driving performance of chronically administered buspirone and diazepam in anxious outpatients. Journal of Clinical Psychopharmacology, 12, 86-95.
26. Von Moltke LL, Greenblatt DJ, Harmatz JS and Shader RI (1994) Editorial. Cytochromes in psychopharmacology. Journal of Clinical Psychopharmacology, 14, 1-4.
27. Wrighton SA, Stevens JC, Becker GW and Vandenbranden M (1993) Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxilation. Archives of Biochemistry Biophysics, 306, 240-245.